Terrascend Corp

Terrascend Corp maintains a capital structure characterized by significant leverage, with total liabilities of $459.9 million against total equity of $97.5 million, resulting in a debt-to-equity ratio of 2.32. The company holds $37.4 million in cash and equivalents, which is insufficient to cover its $226.4 million in long-term debt, leading to a negative net cash position. Liquidity is assessed as medium, supported by a current ratio of 1.38, indicating the ability to meet short-term obligations despite the heavy debt load. The market capitalization stands at $283.5 million, with an enterprise value-to-revenue multiple of 1.8 and an EV/EBITDA of 11.85, reflecting the market's valuation of the company's operational assets relative to its earnings before interest, taxes, depreciation, and amortization.

Profitability metrics indicate significant operational challenges, with a net income loss of $86.2 million against revenues of $260.6 million. The company reports a gross profit of $136.3 million, suggesting a gross margin of approximately 52%, but operating income of $40.6 million is insufficient to cover interest and other expenses, leading to the net loss. Return on equity is negative at -83.8%, and return on assets is -14.7%, highlighting the inefficiency in generating profits from its asset base. Without cohort median data for direct comparison, these figures suggest a company in a high-burn phase typical of development-stage pharmaceutical firms, where R&D and commercialization costs outweigh current earnings.

Revenue concentration and segment details are not explicitly provided in the available data, limiting the analysis of geographic or product-specific exposure. The company's total revenue of $260.6 million serves as the primary indicator of its market presence. In the absence of segment breakdowns, it is assumed that revenue is derived from its core pharmaceutical activities, with no disclosed diversification into other business lines. This lack of granularity prevents a detailed assessment of revenue concentration risk, but the single-industry classification suggests a focused business model.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot shows a revenue base of $260.6 million, but without year-over-year or quarterly trend data, the direction and velocity of revenue growth cannot be quantified. The negative free cash flow of $18.2 million, driven by operating cash flow of $21.5 million and capital expenditures of $9.4 million, indicates that the company is consuming cash to fund its operations and investments, a common pattern in growth-oriented pharmaceutical companies that have not yet achieved sustainable profitability.

Risk assessment identifies medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which poses a refinancing risk if debt maturities approach. The low dilution risk suggests that the company is not currently issuing significant new shares, which is supported by the identical basic and diluted share counts of 373.1 million. However, the high debt-to-equity ratio and negative net income create a fragile financial position that could be exacerbated by rising interest rates or a downturn in the pharmaceutical sector.

Recent observations from investor relations indicate a mean analyst price target of $1.83, with a median target of $2.00, suggesting that analysts expect significant upside from the current market price of $0.76. The mean recommendation is 2.00, with three buy ratings and no hold or sell ratings, indicating a bullish sentiment among covering analysts. There are no strong buy ratings, but the absence of negative ratings suggests a consensus view of potential value realization, likely tied to the commercial success of its pharmaceutical products.

Operating income grew 10.2% year-over-year to $40.6 million, demonstrating improving core profitability despite net losses.

Revenue grew at a 5.5% CAGR over four years, showing consistent top-line expansion in the pharmaceutical sector.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Debt-to-equity ratio of 2.32 is in the bottom quartile versus peers, indicating excessive leverage and high credit risk.

Revenue $65.5M, +1,9% YoY; Operating income −5,9% YoY.

• ▍Revenue $65.5M, +1,9% YoY
• ▍Operating income −5,9% YoY
• ▍Net income +33,2% YoY
• ▍Free cash flow +47,4% YoY
• ▍Net margin -13.8%

Revenue $66.1M, −0,5% YoY; Operating income −34,3% YoY.

• ▍Revenue $66.1M, −0,5% YoY
• ▍Operating income −34,3% YoY
• ▍Net income +107,8% YoY
• ▍Free cash flow −79,7% YoY
• ▍Net margin 3.8%

Revenue $65.1M, −0,1% YoY; Operating income +88,2% YoY.

• ▍Revenue $65.1M, −0,1% YoY
• ▍Operating income +88,2% YoY
• ▍Net income −11,3% YoY
• ▍Free cash flow +31,5% YoY
• ▍Net margin -39.6%

Revenue $65.0M, −3,3% YoY; Operating income +3,1% YoY.

• ▍Revenue $65.0M, −3,3% YoY
• ▍Operating income +3,1% YoY
• ▍Net income −503,7% YoY
• ▍Free cash flow −11,6% YoY
• ▍Net margin -76.0%

Revenue $64.3M; Operating income $12.2M.

• ▍Revenue $64.3M
• ▍Operating income $12.2M
• ▍Net margin -21.1%

Revenue $66.4M; Operating income $11.7M.

• ▍Revenue $66.4M
• ▍Operating income $11.7M
• ▍Net margin -47.9%

Revenue $65.2M; Operating income $5.2M.

• ▍Revenue $65.2M
• ▍Operating income $5.2M
• ▍Net margin -35.5%

Revenue $67.2M; Operating income $10.6M.

• ▍Revenue $67.2M
• ▍Operating income $10.6M
• ▍Net margin -12.2%

Revenue $260.6M, −2,8% YoY; Operating income +10,2% YoY.

• ▍Revenue $260.6M, −2,8% YoY
• ▍Operating income +10,2% YoY
• ▍Net income −7,5% YoY
• ▍Free cash flow −12,1% YoY
• ▍Net margin -33.1%

Revenue $268.1M, +7,0% YoY; Operating income +25,3% YoY.

• ▍Revenue $268.1M, +7,0% YoY
• ▍Operating income +25,3% YoY
• ▍Net income +16,0% YoY
• ▍Free cash flow +24,2% YoY
• ▍Net margin -29.9%

Revenue $250.5M, +1,1% YoY; Operating income +108,7% YoY.

• ▍Revenue $250.5M, +1,1% YoY
• ▍Operating income +108,7% YoY
• ▍Net income +71,0% YoY
• ▍Free cash flow +93,2% YoY
• ▍Net margin -38.1%

Revenue $247.8M, +17,8% YoY; Operating income −7 000,9% YoY.

• ▍Revenue $247.8M, +17,8% YoY
• ▍Operating income −7 000,9% YoY
• ▍Net income −10 704,6% YoY
• ▍Free cash flow −1 725,8% YoY
• ▍Net margin -133.1%